Literature DB >> 25740464

Aspirin in secondary prevention of recurrent venous thromboembolism.

Kochawan Boonyawat1, Mark A Crowther.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25740464     DOI： 10.1007/s11239-015-1196-4

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  24 in total

1.  Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration.

Authors:  John Simes; Cecilia Becattini; Giancarlo Agnelli; John W Eikelboom; Adrienne C Kirby; Rebecca Mister; Paolo Prandoni; Timothy A Brighton
Journal:  Circulation       Date:  2014-08-25       Impact factor: 29.690

2.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Clive Kearon; Elie A Akl; Anthony J Comerota; Paolo Prandoni; Henri Bounameaux; Samuel Z Goldhaber; Michael E Nelson; Philip S Wells; Michael K Gould; Francesco Dentali; Mark Crowther; Susan R Kahn
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study.

Authors:  M Milan; F Noventa; A Ghirarduzzi; V Pengo; V Vedovetto; L Filippi; E Campello; P Prandoni
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

4.  Aspirin for preventing the recurrence of venous thromboembolism.

Authors:  Cecilia Becattini; Giancarlo Agnelli; Alessandro Schenone; Sabine Eichinger; Eugenio Bucherini; Mauro Silingardi; Marina Bianchi; Marco Moia; Walter Ageno; Maria Rita Vandelli; Elvira Grandone; Paolo Prandoni
Journal:  N Engl J Med       Date:  2012-05-24       Impact factor: 91.245

5.  Extended use of dabigatran, warfarin, or placebo in venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Sebastian Schellong; Henry Eriksson; David Baanstra; Anne Mathilde Kvamme; Jeffrey Friedman; Patrick Mismetti; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2013-02-21       Impact factor: 91.245

6.  Apixaban for extended treatment of venous thromboembolism.

Authors:  Giancarlo Agnelli; Harry R Buller; Alexander Cohen; Madelyn Curto; Alexander S Gallus; Margot Johnson; Anthony Porcari; Gary E Raskob; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2012-12-08       Impact factor: 91.245

7.  Collaborative overview of randomised trials of antiplatelet therapy--III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-22

Review 8.  Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.

Authors:  Madeleine Verhovsek; James D Douketis; Qilong Yi; Sanjay Shrivastava; R Campbell Tait; Trevor Baglin; Daniela Poli; Wendy Lim
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

9.  Trial of dipyridamole-aspirin in recurring venous thrombosis.

Authors:  P Steele
Journal:  Lancet       Date:  1980 Dec 20-27       Impact factor: 79.321

10.  Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.

Authors:  Paolo Prandoni; Martin H Prins; Anthonie W A Lensing; Angelo Ghirarduzzi; Walter Ageno; Davide Imberti; Gianluigi Scannapieco; Giovanni B Ambrosio; Raffaele Pesavento; Stefano Cuppini; Roberto Quintavalla; Giancarlo Agnelli
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391
View more
  1 in total

1.  Aspirin-Loaded Polymeric Films for Drug Delivery Systems: Comparison between Soaking and Supercritical CO2 Impregnation.

Authors:  Isabela Trindade Coutinho; Lígia Passos Maia-Obi; Mathilde Champeau
Journal:  Pharmaceutics       Date:  2021-06-02       Impact factor: 6.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.